Faron Pharmaceuticals (FARN) investor relations material

Clinical trial results and efficacy

• Bexmarilimab combined with azacitidine achieved a 45% complete remission rate and 85% overall response rate in frontline high-risk MDS, with responses maintained over time and 60% of patients achieving full clearance of bone marrow blasts.

• Median duration of complete remission reached 16.1 months, an improvement from previous reports and favorable compared to azacitidine alone.

• TP53-mutated patients, typically with poor outcomes, achieved a 70% complete remission rate.

• HMA-failed MDS patients had a 64% overall response rate, indicating benefit even in refractory populations.

• Data support the initiation of a randomized Phase IIb trial, with CR as a key regulatory endpoint.

Safety and tolerability

• Safety profile remains promising and similar to azacitidine alone, with no Bexmarilimab-related deaths reported.

• Most common adverse events were hematopoietic toxicities, such as febrile neutropenia (32.7%).

• The combination is considered well-tolerated in a frail, elderly patient population.

• Safety and tolerability profile remains stable and well tolerated in elderly, high-risk patients.

Mechanism of action and biomarker insights

• Bexmarilimab targets Clever-1, reprogramming macrophages from an immunosuppressive to an immunostimulatory state, enhancing immune activation and hematopoiesis, and may improve mitochondrial function in myeloid blast cells.

• Treatment increased hematopoietic progenitor cells, cytotoxic CD8 T cells, basophil/mast cell and erythroid progenitor populations, while reducing exhausted TIM-3 positive T cells.

• Baseline immune profiling showed higher central memory T cells in CR responders, indicating a favorable pre-existing immune context.

• Patients achieving complete remission showed stronger T cell activation and memory T cell differentiation.

• Strong correlation observed between Clever-1 target engagement and clinical response.